Ambeylab

India Listed

Agrochemical intermediates and formulations are manufactured for crop protection.

Page last updated 19 Oct 2026

About Ambeylab

Ambeylab is a publicly listed company based in India. Agrochemical intermediates and formulations are manufactured for crop protection. The company has 88 employees. Its Indian entity Dhansa Labs Limited reported revenue of ₹143 Cr. Ambeylab offers products and services including 2,4-D Acid 98% TC, 2,4-D Sodium 95% SP, 2,4-D Amine 866g/l SL, 2,4-D Ethyl Hexyl Ester 96% TC, and 2,4-D Ethyl Ester 96% TC. Its focus areas include Food and Agriculture and Crop Inputs.

Company details

Agrochemical intermediates and formulations are produced by Ambeylab, an India-based entity in the agricultural chemicals sector. Operations involve the creation of products aimed at controlling diseases, weeds, fungi, and insects in crops. Manufacturing processes are maintained to facilitate distribution across global markets, with supplies directed toward various agricultural applications.

Headquarters India
Employees 88
Stage Public
Sectors
Agriculture
Website ambeylab.com
Legal Name Dhansa Labs Limited

Operational Areas

Agriculture → Crop Inputs & Fertilizers

Key Metrics

Market Cap
₹63.63 Cr
DHANSA-ST · NSE
Share Price
₹23.65
0.00% today
Revenue
₹142 Cr
FY 2025-26
EBITDA
₹10.91 Cr
Margin 7.7%
Net Profit
₹5.50 Cr
FY 2025-26
P/E (TTM)
12.1x
P/B 0.8x
ROE
6.2%
ROCE 7.8%
Debt / Equity
0.45
Interest cover 30.2x
Employee Count
88

Associated legal entities of Ambeylab

Ambeylab operates through Dhansa Labs Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Dhansa Labs Limited Listed CIN L74899DL1985PLC020490	Active	20 Mar 1985	New Delhi, Delhi	₹143 Cr	88	8	View details

Products & Services of Ambeylab

Ambeylab offers a comprehensive portfolio of products and services, including 2,4-D Acid 98% TC, 2,4-D Sodium 95% SP, 2,4-D Amine 866g/l SL, 2,4-D Ethyl Hexyl Ester 96% TC, and 2,4-D Ethyl Ester 96% TC.

2,4-D Acid 98% TC

Agrochemical

Herbicide for controlling weeds in various crops.

2,4-D Sodium 95% SP

Agrochemical

Weed control agent for agricultural applications.

2,4-D Amine 866g/l SL

Agrochemical

Herbicide formulation to manage crop weeds effectively.

2,4-D Ethyl Hexyl Ester 96% TC

Agrochemical

Chemical for weed suppression in farming.

2,4-D Ethyl Ester 96% TC

Agrochemical

Herbicide used in crop protection programs.

Chlorpyriphos 97% TC

Agrochemical

Insecticide to combat harmful pests in crops.

Thiamethoxam 96% TC

Agrochemical

Insecticide for protecting plants from insects.

Pretilachlor 95% TC

Agrochemical

Herbicide to control weeds in rice fields.

Metribuzin 97% TC

Agrochemical

Weed management solution for various crops.

Hexaconazole 92% TC

Agrochemical

Fungicide against crop diseases and fungi.

Board of directors of Dhansa Labs Limited (Ambeylab)

Dhansa Labs Limited is the primary company behind Ambeylab. The board of Dhansa Labs Limited currently have 5 directors; the longest-serving is Roni Soni, appointed in 2023. 12 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Roni Soni DIN 07504677	Director	20 Jul 2023	3 yrs 3 mo	Dhansa Labs Limited
Abdul Quadir DIN 09781856	Director	30 Sep 2023	3 yrs	Dhansa Labs Limited
Archit Gupta DIN 00378409	Whole-time director	02 Sep 2025	1 yr 1 mo	Dhansa Labs Limited
Arpit Gupta DIN 01876092	Director	02 Sep 2025	1 yr 1 mo	Dhansa Labs Limited
Bharti Kashyap DIN 08416005	Director	02 Sep 2025	1 yr 1 mo	Dhansa Labs Limited

IPO & Listings of Ambeylab

Ambeylab is a publicly listed company on the NSE with ticker symbol DHANSA in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date11 Jul 2024
Listed onNSE: DHANSA
Listed entityDhansa Labs Limited
Exchange sectorProcess industries
ISININE0M3I01029
Share price₹26.10 (-4.92% on the day) · 2026-10-13
Market capitalisation₹73.8 Cr
Price to earnings11.8
EPS (diluted, trailing year)₹2.21
Volume (last session)6,000

Financials of Ambeylab

Exchange-reported figures of Dhansa Labs Limited, the listed company behind Ambeylab (NSE: DHANSA-ST).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹142 Cr

EBITDA

₹10.91 Cr

Profit After Tax

₹5.50 Cr

Net Worth

₹98.86 Cr

Total Assets

₹139 Cr

Total Debt

₹39.67 Cr

Financial summary ₹ Cr

Metrics	FY 2025-26
Income statement
Revenue	142
EBITDA	10.91
EBITDA margin	+7.7%
Profit before tax	7.39
Net profit	5.50
Net profit margin	+3.9%
EPS (₹)	2.21
Balance sheet
Total assets	139
Net worth	98.86
Total debt	39.67
Cash & bank	2.50
Net working capital	89.23
Cash flow
Cash from operations	(4.37)
Cash from investing	(48.18)
Cash from financing	54.02

Particulars	Jun 2026	Mar 2026	Dec 2025
Revenue	30.56	40.54	32.82
Other income	0.03	0.88	0.30
EBITDA	2.64	2.45	2.57
EBITDA margin	+8.6%	+6.0%	+7.8%
Depreciation	0.44	0.54	0.55
Interest	0.71	0.38	0.32
Profit before tax	1.52	2.41	2.00
Tax	0.80	0.40	1.09
Net profit	0.72	2.01	0.91
EPS (₹)	0.28	0.80	0.36

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Income statement
Revenue	142	131	120	105	84.60	81.74
Revenue growth	+7.8%	+9.0%	+14.9%	+23.9%	+3.5%	-
EBITDA	10.92	9.60	8.43	7.79	10.34	9.75
EBITDA margin	+7.7%	+7.3%	+7.0%	+7.4%	+12.2%	+11.9%
Profit before tax	7.60	6.03	5.43	5.51	4.82	3.10
Net profit	5.71	4.63	7.97	5.30	3.56	10.35
Net profit margin	+4.0%	+3.5%	+6.6%	+5.1%	+4.2%	+12.7%
EPS (₹)	2.30	1.92	4.13	29.52	20.14	211.23
Balance sheet
Total assets	139	118	61.69	33.26	38.09	26.03
Net worth	99.07	76.35	31.51	19.14	19.07	(7.87)
Total debt	39.57	40.84	29.64	14.13	18.04	32.93
Cash & bank	2.39	1.76	0.38	0.41	0.29	0.51
Net working capital	88.77	77.04	29.91	6.61	6.57	1.54
Cash flow
Cash from operations	(1.00)	(34.48)	(13.15)	10.05	5.61	2.74
Cash from investing	(11.28)	(13.50)	(5.28)	(3.69)	(0.75)	(1.17)
Cash from financing	12.92	48.34	18.39	(6.23)	(5.08)	(1.49)

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	30.56	40.54	32.82	39.89	28.29	30.55	33.07
Revenue growth (YoY)	+8.0%	+32.7%	-0.8%	-	-	-	-
Other income	0.63	1.08	0.30	0.11	0.02	0.86	0.28
Total expenses	27.91	38.21	30.13	36.86	25.43	28.20	31.67
EBITDA	2.65	2.33	2.69	3.03	2.86	2.35	1.40
EBITDA margin	+8.7%	+5.7%	+8.2%	+7.6%	+10.1%	+7.7%	+4.2%
Depreciation	0.44	0.54	0.55	1.37	0.55	0.67	0.09
Interest	0.71	0.38	0.32	0.10	1.00	1.00	0.71
Profit before tax	2.13	2.49	2.12	1.67	1.33	1.54	0.88
Tax	0.80	0.40	1.09	0.24	0.14	0.38	0.23

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026

Particulars	Jun 2026	Mar 2026	Dec 2025
Revenue	30.56	40.54	32.82
Other income	0.03	0.88	0.30
EBITDA	2.64	2.45	2.57
EBITDA margin	+8.6%	+6.0%	+7.8%
Depreciation	0.44	0.54	0.55
Interest	0.71	0.38	0.32
Profit before tax	1.52	2.41	2.00
Tax	0.80	0.40	1.09
Net profit	0.72	2.01	0.91
EPS (₹)	0.28	0.80	0.36

Particulars	FY 2025-26
Revenue	142
Other income	1.31
Total expenses	131
Employee cost	1.02
EBITDA	10.91
EBITDA margin	+7.7%
Depreciation	2.20
Interest	2.63
Profit before tax	7.39
Tax	1.87
Net profit	5.50
Net profit margin	+3.9%
EPS (₹)	2.21

Particulars	FY 2025-26
Equity & liabilities
Share capital	24.95
Reserves & surplus	56.93
Shareholders' funds (net worth)	98.86
Minority interest	0.00
Secured loans	39.57
Unsecured loans	0.10
Total debt	39.67
Total liabilities	139
Assets
Gross block	61.56
Net block	24.32
Capital work in progress	22.78
Investments	0.00
Inventories	31.54
Sundry debtors	53.90
Cash & bank balances	2.50
Loans & advances	13.27
Total current assets	101
Total current liabilities	11.98
Net working capital	89.23
Total assets	139

Particulars	FY 2025-26
Opening cash	0.00
Net cash from operating activities	(4.37)
Net cash from investing activities	(48.18)
Net cash from financing activities	54.02
Net change in cash	1.48
Closing cash	2.50

Particulars	FY 2025-26
Growth
PBT growth	+9997.0%
Profitability & leverage
Net income margin	+3.9%
Return on capital employed	+7.8%
Return on net worth	+6.3%
Debt / equity	0.45
Long-term debt / equity	0.21
Interest cover	30.20
Efficiency & per share
Fixed asset turnover	2.77
Inventory turnover	4.49
Debtors turnover	2.63
EPS (₹)	2.21
Dividend per share (₹)	0.00
Book value per share (₹)	28.61

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	30.56	40.54	32.82	39.89	28.29	30.55	33.07
Revenue growth (YoY)	+8.0%	+32.7%	-0.8%	-	-	-	-
Other income	0.63	1.08	0.30	0.11	0.02	0.86	0.28
Total expenses	27.91	38.21	30.13	36.86	25.43	28.20	31.67
EBITDA	2.65	2.33	2.69	3.03	2.86	2.35	1.40
EBITDA margin	+8.7%	+5.7%	+8.2%	+7.6%	+10.1%	+7.7%	+4.2%
Depreciation	0.44	0.54	0.55	1.37	0.55	0.67	0.09
Interest	0.71	0.38	0.32	0.10	1.00	1.00	0.71
Profit before tax	2.13	2.49	2.12	1.67	1.33	1.54	0.88
Tax	0.80	0.40	1.09	0.24	0.14	0.38	0.23

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Revenue	142	131	120	105	84.60	81.74
Revenue growth	+7.8%	+9.0%	+14.9%	+23.9%	+3.5%	-
Other income	1.51	1.92	1.59	2.77	0.51	0.68
Total expenses	131	122	112	97.03	74.26	71.99
Employee cost	1.02	1.36	1.38	2.21	1.70	1.68
EBITDA	10.92	9.60	8.43	7.79	10.34	9.75
EBITDA margin	+7.7%	+7.3%	+7.0%	+7.4%	+12.2%	+11.9%
Depreciation	2.20	2.54	2.17	2.96	2.97	3.22
Interest	2.63	2.95	2.42	2.09	3.06	4.11
Profit before tax	7.60	6.03	5.43	5.51	4.82	3.10
Tax	1.87	1.26	(2.29)	0.26	1.26	(7.25)
Net profit	5.71	4.63	7.97	5.30	3.56	10.35
Net profit margin	+4.0%	+3.5%	+6.6%	+5.1%	+4.2%	+12.7%
EPS (₹)	2.30	1.92	4.13	29.52	20.14	211.23

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Equity & liabilities
Share capital	24.95	24.95	18.69	17.75	17.75	4.89
Reserves & surplus	57.14	51.40	12.82	1.39	1.32	(12.76)
Shareholders' funds (net worth)	99.07	76.35	31.51	19.14	19.07	(7.87)
Secured loans	39.57	40.84	28.91	11.36	14.13	16.34
Unsecured loans	0.00	0.00	0.73	2.77	3.91	16.59
Total debt	39.57	40.84	29.64	14.13	18.04	32.93
Total liabilities	139	118	61.69	33.26	38.09	26.03
Assets
Gross block	58.23	58.35	57.10	56.17	53.08	40.87
Net block	20.99	23.11	23.97	25.21	25.09	15.85
Capital work in progress	22.04	15.66	3.84	0.00	0.00	0.95
Investments	0.10	0.00	0.78	0.60	0.00	0.00
Inventories	31.54	29.91	20.57	17.12	10.75	8.73
Sundry debtors	53.90	40.43	18.69	3.57	8.52	6.97
Cash & bank balances	2.39	1.76	0.38	0.41	0.29	0.51
Loans & advances	11.19	14.42	7.99	6.22	4.85	3.92
Total current assets	99.02	86.52	47.63	27.32	24.41	20.13
Total current liabilities	10.25	9.48	17.72	20.71	17.84	18.59
Net working capital	88.77	77.04	29.91	6.61	6.57	1.54
Total assets	139	118	61.69	33.26	38.09	26.03

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Opening cash	0.73	0.37	0.40	0.27	0.51	0.43
Net cash from operating activities	(1.00)	(34.48)	(13.15)	10.05	5.61	2.74
Net cash from investing activities	(11.28)	(13.50)	(5.28)	(3.69)	(0.75)	(1.17)
Net cash from financing activities	12.92	48.34	18.39	(6.23)	(5.08)	(1.49)
Net change in cash	0.64	0.36	(0.03)	0.13	(0.22)	0.09
Closing cash	2.39	1.76	0.38	0.41	0.29	0.51

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Growth
Sales growth	+7.8%	+9.0%	+14.9%	+23.9%	+3.5%	-
EBITDA growth	+13.8%	+13.9%	+8.2%	-24.7%	+6.1%	-
PBT growth	+26.0%	+11.1%	-1.5%	+14.3%	+55.5%	+9997.0%
Net income growth	+23.3%	-41.9%	+50.4%	+48.9%	-65.6%	-
Revenue CAGR (3Y)	+10.5%	+15.8%	+13.8%	-	-	-
EBITDA CAGR (3Y)	+11.9%	-2.4%	-4.7%	-	-	-
Profitability & leverage
Net income margin	+4.1%	+3.6%	+6.4%	+5.0%	+4.2%	+12.7%
Return on capital employed	+8.7%	+11.3%	+18.6%	+22.1%	+20.9%	+18.6%
Return on net worth	+7.4%	+10.8%	+38.5%	+29.5%	+31.5%	+211.5%
Debt / equity	0.52	0.81	1.48	1.87	72.82	0.00
Long-term debt / equity	0.19	0.31	1.00	1.54	60.10	0.00
Interest cover	30.16	41.78	38.66	43.27	41.52	62.94
Efficiency & per share
Fixed asset turnover	2.96	2.78	2.61	2.38	2.03	2.00
Inventory turnover	4.61	5.20	6.39	7.52	8.69	9.36
Debtors turnover	3.00	4.44	10.82	17.34	10.92	11.73
EPS (₹)	2.30	1.92	4.13	29.52	20.14	211.23
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	28.69	26.40	11.24	48.69	48.26	(160.70)

Top companies in Crop Inputs & Fertilizers

3 companies that operate in the same segment as Ambeylab (Crop Inputs & Fertilizers) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
DFPCL	Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate	1979	Pune, Maharashtra, India		USD 1.21 B	1,020
Safex Chemicals	Manufacturer of agrochemicals for crop protection	1991	Delhi, Delhi, India	USD 88.79 M	USD 165.62 M	449
Crystal Crop Protection	Agrochemicals and equipment for crop protection are manufactured.	1994	Delhi, Delhi, India	USD 28.03 M	USD 303.27 M	1,262

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Ambeylab

Where is Ambeylab located?

Ambeylab is headquartered in India.

How many employees does Ambeylab have?

Ambeylab has 88 employees.

What is the annual revenue of Ambeylab?

The primary company behind Ambeylab, Dhansa Labs Limited, reported revenue of ₹143 Cr for FY 2026, up 9997% year on year.

What does Ambeylab do?

What products or services does Ambeylab offer?

Ambeylab offers 2,4-D Acid 98% TC, 2,4-D Sodium 95% SP, 2,4-D Amine 866g/l SL, 2,4-D Ethyl Hexyl Ester 96% TC, and 6 more products and services.

Is Ambeylab publicly traded?

Yes, Ambeylab is publicly traded on NSE under the ticker symbol DHANSA.

Which legal entities are associated with Ambeylab?

Ambeylab operates through Dhansa Labs Limited.

Who are the directors of Ambeylab?

The legal entities of Ambeylab currently have 7 directors, including Archit Gupta, Arpit Gupta, Abdul Quadir and others.

About Ambeylab

Company details

Operational Areas of Ambeylab

Associated legal entities of Ambeylab

Products & Services of Ambeylab

Board of directors of Dhansa Labs Limited (Ambeylab)

IPO & Listings of Ambeylab

Financials of Ambeylab

Financial Highlights

Financial summary ₹ Cr Consolidated Standalone AnnualQuarterly

Financial Statements

Top companies in Crop Inputs & Fertilizers

Frequently Asked Questions about Ambeylab

Financial summary ₹ Cr